Physician profile
Lynsey L Lakin
NPI 1861890030
$540,171.01
in general payments reported to CMS, 2019-2025
49 companies · $210K in 2025
The $210K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58K · 2022: $63K · 2023: $54K · 2024: $154K · 2025: $210K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $278K · Travel and Lodging: $79K · Food and Beverage: $27K · Consulting Fee: $25K · Honoraria: $7,356 · Grant: $2,500 · Education: $53.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $277,902.00 |
| Travel and Lodging | $79,282.24 |
| Food and Beverage | $26,661.70 |
| Consulting Fee | $25,204.00 |
| Honoraria | $7,356.25 |
| Grant | $2,500.00 |
| Education | $53.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $249,476.31 | 2021-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $82,620.98 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Alexion Pharmaceuticals, INC. | $45,620.71 | 2021-2025 | Ultomiris, Soliris |
| Abbvie INC. | $36,104.76 | 2021-2025 | |
| Ucb, INC. | $26,933.79 | 2023-2025 | Rystiggo, Zilbrysq |
| Genentech USA, INC. | $21,558.93 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Genzyme Corporation | $15,658.46 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $12,915.50 | 2021-2025 | |
| Tg Therapeutics, INC. | $10,353.02 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $8,922.61 | 2022 | |
| Amgen INC. | $6,692.81 | 2021-2025 | Uplizna |
| Ani Pharmaceuticals, INC. | $6,575.93 | 2024-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $5,761.78 | 2023-2025 | |
| Horizon Therapeutics Plc | $4,132.88 | 2022-2023 | Uplizna |
| Allergan, INC. | $1,985.92 | 2021-2022 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $875.09 | 2021-2025 | Nuplazid |
| Celgene Corporation | $646.18 | 2021-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $588.76 | 2021-2024 | Austedo Xr |
| Ipsen Biopharmaceuticals, INC | $285.13 | 2023-2025 | Dysport |
| Argenx US, INC. | $203.65 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $171.69 | 2021-2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $159.12 | 2023-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $150.85 | 2021-2025 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $150.00 | 2021 | |
| Eisai INC. | $142.26 | 2023-2025 | |
| Lilly USA, LLC | $140.96 | 2022-2024 | Emgality, Kisunla, Reyvow |
| Boston Scientific Corporation | $135.10 | 2021-2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Biohaven Pharmaceuticals, INC. | $131.82 | 2021 | |
| Mallinckrodt Hospital Products INC. | $103.77 | 2021-2024 | Acthar |
| Banner Life Sciences, LLC | $95.85 | 2023-2024 | |
| Merz Pharmaceuticals, LLC | $94.16 | 2024-2025 | Xeomin, Inbrija |
| Octapharma USA, INC. | $90.49 | 2022 | |
| Cycle Pharmaceuticals INC | $82.34 | 2025 | Tascenso Odt, Bafiertam |
| Neurocrine Biosciences, INC. | $76.91 | 2022 | |
| Janssen Pharmaceuticals, INC | $75.84 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $75.68 | 2023 | |
| Sk Life Science, INC. | $53.76 | 2024-2025 | |
| Avanir Pharmaceuticals, INC. | $40.42 | 2022 | |
| Amneal Pharmaceuticals LLC | $37.47 | 2024-2025 | Crexont, Rytary |
| Terumo Bct, INC. | $36.48 | 2022 | |
| Immedica Pharma US, INC. | $33.61 | 2022 | |
| Acorda Therapeutics, INC | $27.93 | 2023 | Ampyra, Inbrija |
| Alnylam Pharmaceuticals INC. | $27.48 | 2023 | Amvuttra |
| Tanabe Pharma America, INC. | $27.30 | 2024 | |
| Medtronic, INC. | $25.57 | 2023 | Vanta Adaptivestim |
| Ge Healthcare | $24.13 | 2025 | |
| Glaxosmithkline, LLC. | $17.57 | 2024 | Shingrix |
| Janssen Biotech, INC. | $15.25 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynsey Lakin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.